Last updated: 2026-09-16 09:46:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
iBio, Inc. (IBIO) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1.24, with a market capitalisation of $77.17M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.77 to $3.82. This page covers its latest market performance, valuation, price trends and company information.
$77.17M | |
$1.20 | |
$30,300.00 | |
$0.56 | |
$1.19 | |
4.49K | |
812.75K | |
-- | |
$3.82 | |
$0.77 | |
-- | |
-- |
iBio, Inc. (IBIO) is trading at $1.24 in pre-market trading as of 2026-09-16 09:26:00, up 4.12% ($0.05) from the previous close of $1.19
Pre-market trading shows how investors are pricing IBIO before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, iBio, Inc. (IBIO) moved from $1.31 to $1.24, representing a decline of 5.42% ($0.07).
The stock traded between $1.17 and $1.33 during the period. The latest price is near the middle of the 7-day range, indicating strong downward.
The average daily volume was 294.74 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 15.4%
IBIO is currently trading at $1.24, placing it 15.4% of the way from its 52-week low of $0.77 to its 52-week high of $3.82. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
iBio Inc is a clinical-stage biotechnology company using Artificial Intelligence (AI) for the development of hard-to-drug precision antibodies for obesity, cardiometabolic, and cardiopulmonary diseases. Its product candidate pipeline includes IBIO-610, a monoclonal antibody designed to block Activin E; IBIO-800, a bispecific antibody program targeting myostatin, growth differentiation factor 11 (GDF11), and Activin A; IBIO-600; Amylin Antibody; and Target 4, in different stages of development, being developed as potential therapies for obesity and cardiometabolic disease. The company operates as one reportable segment, which is that of a biotechnology company leveraging AI and ML for the development of hard-to-drug precision antibodies.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 23 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of iBio, Inc. (IBIO) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.